Form 4: Bristol-Myers Squibb Executive Benjamin Hickey Reports Sale of Shares
SEC Form 4 Filing
Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reported the sale of company stock by his spouse.
Summary
- On May 9, 2025, Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reported a transaction involving Bristol-Myers Squibb common stock.
- The transaction involved the sale of 97.391 shares of common stock at a price of $38.01 per share by Hickey's spouse.
- Following the transaction, Hickey directly owns 8,789 shares of Bristol-Myers Squibb common stock.
- The sale represents the complete disposition of stock fund units held by Hickey's spouse.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports a transaction.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities. This filing indicates a sale of shares by the spouse of an officer, which may or may not reflect the officer's personal outlook on the company.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it provides insight into insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | Date of the stock sale transaction. |
| 05/13/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Bristol-Myers Squibb, BMY, Insider Trading, Stock Sale, Benjamin Hickey, RayzeBio
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.